Table 5.
Multivariable subhazard ratios and 95% confidence intervals for endometrial recurrence according to NSAID use, stratified by histologic subtype in the NRG Oncology/GOG 210 Study (n = 4374)
| Any NSAID use | Type I endometrial carcinoma |
Type II endometrial carcinoma |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Low-grade endometrioid | High-grade endometrioid | Serous | Carcinosarcoma | Clear cell | Pheterogeneity‡ | ||||||
| (n = 2657) |
(n = 582) |
(n = 663) |
(n = 309) |
(n = 163) |
|||||||
| Recurrences | HR (95% CI)† | Recurrences | HR (95% CI)† | Recurrences No. (%)* | HR (95% CI)† | Recurrences | HR (95% CI)† | Recurrences | HR (95% CI)† | ||
| No. (%)* | No. (%)* | No. (%)* | No. (%)* | ||||||||
| Regular use | .06 | ||||||||||
| Nonuser | 76 (7.5) | 1.00 (reference) | 41 (17.8) | 1.00 (reference) | 94 (40.0) | 1.00 (reference) | 38 (33.6) | 1.00 (reference) | 16 (27.1) | 1.00 (reference) | |
| User | 132 (8.0) | 1.00 (0.74 to 1.35) | 92 (26.1) | 1.54 (1.03 to 2.32) | 149 (34.8) | 0.91 (0.69 to 1.19) | 77 (39.3) | 1.47 (0.97 to 2.23) | 22 (21.1) | 0.60 (0.29 to 1.26) | |
| Recency | |||||||||||
| Nonuser | 76 (7.5) | 1.00 (reference) | 41 (17.8) | 1.00 (reference) | 94 (40.0) | 1.00 (reference) | 38 (33.6) | 1.00 (reference) | 16 (27.1) | 1.00 (reference) | .15 |
| Former | 47 (8.7) | 1.08 (0.74 to 1.57) | 31 (24.6) | 1.42 (0.86 to 2.34) | 57 (40.4) | 1.08 (0.76 to 1.52) | 32 (47.1) | 2.13 (1.28 to 3.55) | 13 (33.3) | 0.78 (0.34 to 1.80) | |
| Current | 63 (6.8) | 0.87 (0.62 to 1.23) | 47 (24.9) | 1.46 (0.93 to 2.29) | 75 (31.8) | 0.86 (0.62 to 1.18) | 40 (35.7) | 1.33 (0.81 to 2.16) | 8 (14.5) | 0.44 (0.18 to 1.08) | |
| Duration, y | |||||||||||
| Nonuser | 76 (7.5) | 1.00 (reference) | 41 (17.8) | 1.00 (reference) | 94 (40.0) | 1.00 (reference) | 38 (33.6) | 1.00 (reference) | 16 (27.1) | 1.00 (reference) | .20 |
| 0.1–4.9 | 54 (8.5) | 1.05 (0.74 to 1.50) | 39 (27.9) | 1.66 (1.03 to 2.67) | 56 (35.2) | 0.90 (0.63 to 1.29) | 19 (32.2) | 1.37 (0.75 to 2.52) | 9 (20.4) | 0.53 (0.24 to 1.19) | |
| 5–9.9 | 16 (6.7) | 0.87 (0.51 to 1.50) | 9 (19.1) | 1.09 (0.49 to 2.44) | 23 (32.9) | 0.91 (0.55 to 1.48) | 11 (37.9) | 1.48 (0.72 to 3.05) | 7 (43.7) | 1.23 (0.36 to 4.15) | |
| ≥10 | 40 (7.6) | 0.97 (0.65 to 1.45) | 25 (23.4) | 1.30 (0.76 to 2.22) | 44 (36.7) | 1.02 (0.70 to 1.49) | 27 (39.7) | 1.55 (0.90 to 2.68) | 4 (16.0) | 0.51 (0.15 to 1.74) | |
| Ptrend§ | .69 | .69 | .66 | .13 | .50 | ||||||
Row percentage. CI = confidence interval; HR = hazard ratio; NSAID = nonsteroidal anti-inflammatory drugs.
Hazard ratios from Fine and Gray semiproportional competing risk model adjusted for age (continuous), stage (I, II, III, IV), ethnicity (white, black, other), education (less than high school, high school/GED, some college/technical school, college graduate), income (<$20 000, $20 000–$39 999, $40 000–$69 999, ≥$70 000 per year), body mass index (<18.5, <25, 25–29.99, 30–34.99, 35–39.99, ≥40 kg/m2), menopausal hormone therapy (none, estrogen only, progestin only, estrogen plus progestin).
Pheterogeneity values based on a two-sided Wald test in regression models corresponding to an interaction term between tumor histology and the corresponding NSAID variable.
Ptrend values were calculated using two-sided orthogonal polynomial contrasts.